Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5274 ARTÍCULOS , VIENDO DEL 2836 AL 2850

Movement-related beta ERD and ERS abnormalities in neuropsychiatric disorders

Peter J, Ferraioli F, Mathew D, George S, Chan C, Alalade T, Salcedo SA, Saed S, Tatti E, Quartarone A, Ghilardi MF.

Front Neurosci. 2022 Nov 23;16:1045715. doi: 10.3389/fnins.2022.1045715. eCollection 2022.

Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease

Schrag A, Carroll C, Duncan G, Molloy S, Grover L, Hunter R, Brown R, Freemantle N, Whipps J, Serfaty MA, Lewis G.

BMC Neurol. 2022 Dec 12;22(1):474. doi: 10.1186/s12883-022-02988-5.

[Delirium after electroconvulsive therapy]

Jaer MZ, Akram MS.

Tidsskr Nor Laegeforen. 2022 Dec 12;142(18). doi: 10.4045/tidsskr.22.0284. Print 2022 Dec 13.

Chronic effects of different exercise types on brain activity in healthy older adults and those with Parkinson's disease: A systematic review

Wang L, Li F, Tang L.

Front Physiol. 2022 Nov 28;13:1031803. doi: 10.3389/fphys.2022.1031803. eCollection 2022.

Magnetic resonance imaging negative myelopathy in Leber's hereditary optic neuropathy: a case report

Martikainen MH, Suomela M, Majamaa K.

BMC Neurol. 2022 Dec 15;22(1):487. doi: 10.1186/s12883-022-03007-3.

COVID-19 pandemic as reflected in Advances in Clinical and Experimental Medicine

Kujawa K, Misiak M, Kurpas D.

Adv Clin Exp Med. 2022 Dec;31(12):1305-1307. doi: 10.17219/acem/157447.

Amyloid management by chaperones: The mystery underlying protein oligomers' dual functions

Arghavani P, Pirhaghi M, Moosavi-Movahedi F, Mamashli F, Hosseini E, Moosavi-Movahedi AA.

Curr Res Struct Biol. 2022 Dec 7;4:356-364. doi: 10.1016/j.crstbi.2022.11.002. eCollection 2022.

The genetic background of Parkinson's disease and novel therapeutic targets

Salamon A, Zádori D, Szpisjak L, Klivényi P, Vécsei L.

Expert Opin Ther Targets. 2022 Oct;26(10):827-836. doi: 10.1080/14728222.2022.2153037. Epub 2022 Dec 16.

Application and progress of transcranial substantial ultrasound in Parkinson's disease

Ma X, Li T, Du L, Han T.

Front Neurol. 2022 Dec 1;13:1091895. doi: 10.3389/fneur.2022.1091895. eCollection 2022.

The effects of bioactive components from the rhizome of gastrodia elata blume (Tianma) on the characteristics of Parkinson's disease

Lu C, Qu S, Zhong Z, Luo H, Lei SS, Zhong HJ, Su H, Wang Y, Chong CM.

Front Pharmacol. 2022 Nov 30;13:963327. doi: 10.3389/fphar.2022.963327. eCollection 2022.

Cognitive impairment, anxiety and depression: a map of Cochrane evidence relevant to rehabilitation for people with post COVID-19 condition

Cordani C, Young VM, Arienti C, Lazzarini SG, Del Furia MJ, Negrini S, Kiekens C.

Eur J Phys Rehabil Med. 2022 Dec;58(6):880-887. doi: 10.23736/S1973-9087.22.07813-3. Epub 2022 Dec 19.

The role of glial cell line-derived neurotrophic factor isoforms in human glial tumors

Revishchin AV, Parshina VV, Pavlova GV.

Zh Vopr Neirokhir Im N N Burdenko. 2022;86(6):106-112. doi: 10.17116/neiro202286061106.

Orchestration of selective autophagy by cargo receptors

Adriaenssens E, Ferrari L, Martens S.

Curr Biol. 2022 Dec 19;32(24):R1357-R1371. doi: 10.1016/j.cub.2022.11.002.

Polymeric nanoparticles for dopamine and levodopa replacement in Parkinson's disease

Alabrahim OAA, Azzazy HME.

Nanoscale Adv. 2022 Nov 3;4(24):5233-5244. doi: 10.1039/d2na00524g. eCollection 2022 Dec 6.

[Triple combination of levodopa, carbidopa and entacapone by intrajejunal pump in advanced Parkinson's disease]

Györfi B, Baló B, Botz K, Jost WH.

Ideggyogy Sz. 2022 Nov 30;75(11-12):365-368. doi: 10.18071/isz.75.0365.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias